Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Can stereotactic radiofrequency ablation replace liver resection?

Can stereotactic radiofrequency ablation replace liver resection? Percutaneous radiofrequency ablation (RFA) is a minimal invasive potentially curative local ablative tumour treatment with very low morbidity and mortality rates as compared to surgery. The question arises whether RFA can replace liver resection. Recent studies have shown that patient long-term survival data after RFA approach the resection data despite inclusion of patients with a poorer prognosis due to comorbidities or disadvantageous tumour distribution. However, since most of the data still favour resection conventional RFA is currently only considered the primary local tumour treatment in combination with surgery or in patients with unresectable colorectal liver metastases (CRLM). Recent improvements in ablation technology and the application of stereotaxy for probe placement have led to local control rates approaching the rates of R0 resections. If stereotactic radiofrequency ablation (SRFA) achieves similar survival rates as compared to resection it may be the method of first choice in patients with potentially resectable colorectal liver metastases. Randomised controlled studies comparing resection and SRFA could finally answer the title question. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Can stereotactic radiofrequency ablation replace liver resection?

Loading next page...
 
/lp/springer-journals/can-stereotactic-radiofrequency-ablation-replace-liver-resection-SA0DKrylOE
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0266-3
Publisher site
See Article on Publisher Site

Abstract

Percutaneous radiofrequency ablation (RFA) is a minimal invasive potentially curative local ablative tumour treatment with very low morbidity and mortality rates as compared to surgery. The question arises whether RFA can replace liver resection. Recent studies have shown that patient long-term survival data after RFA approach the resection data despite inclusion of patients with a poorer prognosis due to comorbidities or disadvantageous tumour distribution. However, since most of the data still favour resection conventional RFA is currently only considered the primary local tumour treatment in combination with surgery or in patients with unresectable colorectal liver metastases (CRLM). Recent improvements in ablation technology and the application of stereotaxy for probe placement have led to local control rates approaching the rates of R0 resections. If stereotactic radiofrequency ablation (SRFA) achieves similar survival rates as compared to resection it may be the method of first choice in patients with potentially resectable colorectal liver metastases. Randomised controlled studies comparing resection and SRFA could finally answer the title question.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 30, 2011

References